U.S. markets open in 7 hours
  • S&P Futures

    3,815.00
    -19.00 (-0.50%)
     
  • Dow Futures

    30,790.00
    -146.00 (-0.47%)
     
  • Nasdaq Futures

    11,749.25
    -59.25 (-0.50%)
     
  • Russell 2000 Futures

    1,730.20
    -11.50 (-0.66%)
     
  • Crude Oil

    100.04
    +0.54 (+0.54%)
     
  • Gold

    1,764.60
    +0.70 (+0.04%)
     
  • Silver

    18.90
    -0.22 (-1.16%)
     
  • EUR/USD

    1.0259
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    2.8090
    0.0000 (0.00%)
     
  • Vix

    27.54
    +0.01 (+0.04%)
     
  • GBP/USD

    1.1930
    -0.0022 (-0.19%)
     
  • USD/JPY

    135.2810
    -0.5610 (-0.41%)
     
  • BTC-USD

    20,009.84
    -361.21 (-1.77%)
     
  • CMC Crypto 200

    432.46
    -7.57 (-1.72%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Altimmune to Present at Upcoming Investor and Scientific Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences:

  • Piper Sandler 33rd Annual Virtual Healthcare Conference
    November 29-December 2, 2021
    Webcast available now

  • 5th Annual NASH Summit 2021
    November 30, 2021
    9:00 am Eastern Time

  • 4th Annual Evercore ISI HealthCONx Conference
    December 2, 2021
    10:55 am Eastern Time

Presentation materials, including webcast links to the Piper Sandler and Evercore ISI presentations, will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com